Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.
Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M. Aller R, et al. Among authors: diago m. Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 7. Gastroenterol Hepatol. 2018. PMID: 29631866 English, Spanish.
Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
Lo Iacono O, Castro A, Diago M, Moreno JA, Fernandez-Bermejo M, Vega P, García V, Carbonell P, Sanz P, Borque MJ, García-Buey L, García-Monzón C, Pedreira J, Moreno-Otero R. Lo Iacono O, et al. Among authors: diago m. Aliment Pharmacol Ther. 2000 Apr;14(4):463-9. doi: 10.1046/j.1365-2036.2000.00713.x. Aliment Pharmacol Ther. 2000. PMID: 10759626 Free article.
Rationale and design of TeraViC-4 study: a phase III, randomized clinical trial to evaluate the effects of treatment duration with peginterferon alfa-2a (40-kDa) and ribavirin in naïve patients with chronic hepatitis C virus infection without early virological response at week 4.
Sánchez-Tapias JM, Crespo J, Diago M, Pérez R, Romero-Gómez M, Muñoz-Sánchez M. Sánchez-Tapias JM, et al. Among authors: diago m. Methods Find Exp Clin Pharmacol. 2002 Nov;24(9):579-84. Methods Find Exp Clin Pharmacol. 2002. PMID: 12616704 Clinical Trial.
Increased circulating and intrahepatic T-cell-specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy.
Apolinario A, Diago M, Lo Iacono O, Lorente R, Pérez C, Majano PL, Clemente G, García-Monzón C. Apolinario A, et al. Among authors: diago m. Aliment Pharmacol Ther. 2004 Mar 1;19(5):551-62. doi: 10.1111/j.1365-2036.2004.01872.x. Aliment Pharmacol Ther. 2004. PMID: 14987324 Free article.
Serum immunological profile in patients with chronic autoimmune cholestasis.
Romero-Gómez M, Wichmann I, Crespo J, Parés A, Rodrigo L, Alvarez A, Diago M, Pons-Romero F, Sanchez-Munoz D, Aguilar-Reina J, Andrade RJ, Salmeron J, Sánchez-Pobre P, Rebollo JM, Martin-Vivaldi R, Castellano-Megias V, Nuñez-Roldan A, Bruguera M; Spanish Group for the Study of Autoimmune Cholangitis. Romero-Gómez M, et al. Among authors: diago m. Am J Gastroenterol. 2004 Nov;99(11):2150-7. doi: 10.1111/j.1572-0241.2004.40416.x. Am J Gastroenterol. 2004. PMID: 15554996
Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.
Romero-Gómez M, Del Mar Viloria M, Andrade RJ, Salmerón J, Diago M, Fernández-Rodríguez CM, Corpas R, Cruz M, Grande L, Vázquez L, Muñoz-De-Rueda P, López-Serrano P, Gila A, Gutiérrez ML, Pérez C, Ruiz-Extremera A, Suárez E, Castillo J. Romero-Gómez M, et al. Among authors: diago m. Gastroenterology. 2005 Mar;128(3):636-41. doi: 10.1053/j.gastro.2004.12.049. Gastroenterology. 2005. PMID: 15765399
Clinical trial: pharmacodynamics and pharmacokinetics of re-treatment with fixed-dose induction of peginterferon alpha-2a in hepatitis C virus genotype 1 true non-responder patients.
Diago M, Crespo J, Olveira A, Pérez R, Bárcena R, Sánchez-Tapias JM, Muñoz-Sánchez M, Romero-Gómez M. Diago M, et al. Aliment Pharmacol Ther. 2007 Oct 15;26(8):1131-8. doi: 10.1111/j.1365-2036.2007.03470.x. Aliment Pharmacol Ther. 2007. PMID: 17894655 Free article. Clinical Trial.
220 results